Biotechnology_ Highlights from our Recent KOL Discussion on Immunotherapy and the Treatment of RCC

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha Biotechnology | North America Highlights from our Recent KOL Discussion on Immunotherapy and the Treatment of RCC We hosted a KOL discussion with a medical oncologist and researcher to discuss his views on the RCC landscape. Key Takeaways On the current 1L metastatic RCC landscape, the KOL outlined his thoughts on immunotherapy doublets (IO/IO) and immunotherapy + TKI combinations (IO/ March 25, 2025 11:47 PM GMT We recently hosted a KOL webcast with the hematology/oncology l ...